30,484 Shares in Johnson & Johnson (JNJ) Acquired by Charter Research & Investment Group Inc.
Charter Research & Investment Group Inc. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 30,484 shares of the company’s stock, valued at approximately $4,259,000. Johnson & Johnson makes up approximately 4.8% of Charter Research & Investment Group Inc.’s portfolio, making the stock its 3rd biggest holding.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Goodman Financial Corp acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $104,000. Price Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $148,000. Roble Belko & Company Inc boosted its position in shares of Johnson & Johnson by 59.7% in the fourth quarter. Roble Belko & Company Inc now owns 1,164 shares of the company’s stock worth $163,000 after buying an additional 435 shares during the period. Cerebellum GP LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $166,000. Finally, Legacy Advisors LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth $202,000. 67.40% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE:JNJ opened at $125.35 on Thursday. Johnson & Johnson has a 1 year low of $125.00 and a 1 year high of $125.73. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. The firm has a market cap of $338.21 billion, a P/E ratio of 17.17, a PEG ratio of 1.93 and a beta of 0.74.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th will be issued a dividend of $0.90 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. This represents a $3.60 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend is Friday, May 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 46.03%.
Several analysts have recently commented on JNJ shares. Jefferies Group set a $165.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, February 26th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 target price for the company in a research report on Tuesday, January 23rd. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $143.00 target price for the company in a research report on Wednesday, March 28th. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, April 17th. Finally, Deutsche Bank reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, April 18th. Five equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Hold” and an average target price of $142.23.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.